Sumatriptan
Synonym(s)
Sumatriptan succinate
DefinitionThis section has been translated automatically.
Serotonin agonist (5-HT1B and 5-HT1D receptor blocker).
Pharmacodynamics (Effect)This section has been translated automatically.
Vasoconstriction of cortical vessels, by stimulation of 5-HT1B and 5-HT1D receptors, which have expanded as a result of an inflammatory reaction during the aura before the onset of pain symptoms Inhibition of the release of pain mediators.
Notice! Sumatriptan is also effective against nausea and vomiting (and thus against the main accompanying symptoms of the migraine attack). Therefore, the additional intake of an antiemetic is not indicated when sumatriptan is used in acute attacks.
IndicationThis section has been translated automatically.
Acute migraine attacks with and without aura, cluster headaches, erythroprosopalgia.
Pregnancy/nursing periodThis section has been translated automatically.
Use during pregnancy only if the expected benefit for the mother outweighs a possible risk to the child (insufficient data available). Lactation period: Sumatriptan passes into breast milk, therefore do not breastfeed for 24-48 hours after application.
Dosage and method of useThis section has been translated automatically.
- Tbl.: 50-100 mg p.o. during the acute attack (maximum daily dose: 100 mg).
- Solution for injection: 6 mg (0,5 ml) s.c. during the acute attack of pain (maximum daily dose 12 mg).
- Suppositories: 1 suppository (25 mg) during the acute attack (maximum daily dose: 50 mg).
- Nasal spray: apply 1 spray (10-20 mg) intranasally during the acute attack (maximum daily dose 20 mg).
Remember! Exceeding the maximum daily dose is not associated with an increased pain-inhibiting effect!
Undesirable effectsThis section has been translated automatically.
Occasional pain, tingling, hyperhidrosis, feelings of heat, heaviness, pressure or tightness in the chest or neck area, stiffness/pain in the neck.
InteractionsThis section has been translated automatically.
Risk of vasospasm when combined with ergotamine derivatives. After comedication with MAO-inhibitors weakness, hyperreflexia and coordination disorders may occur.
ContraindicationThis section has been translated automatically.
Heart attack, ischemic heart disease, coronary vasospasms (Prinzmetal angina), apoplexy, hypertension, comedication with ergotamine derivatives (including methysergide) or MAO inhibitors.
PreparationsThis section has been translated automatically.
Imigran